CClinicalTrials.gg
CompletedNCT01435785TCIGeriatricUpdated Mar 29, 2017

Performance Evaluation of Four Pharmacokinetic-Pharmacodynamic(PKPD) Models of Propofol in Elderly Patients

An observational study in Propofol Overdose of Undetermined Intent, sponsored by Universidad del Desarrollo. Completed at 2 sites in Chile. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Universidad del Desarrollo · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
14
Ages
65 Years and older
Sex
All
01

Study summary

Despite the wide use of propofol target-controlled infusion (TCI) in elderly patients, pharmacokinetic (PK) and pharmacodynamic (PD) models performance has not been prospectively assessed in this population. The aims of this study are to derive four PKPD models using previously published PK parameters sets, and to prospectively assess their performance in elderly people. With the obtained data we propose to build a specific PKPD model for this population.

Read the detailed description

After BIS® and routine monitors were placed, 14 ASA I-II elderly patients (>65 yr) will be anesthetized with plasma TCI of propofol based on Schnider model. After partial recovery from a bolus dose a remifentanil infusion was started and continued throughout surgery. All BIS and TCI data will be continuously record. Arterial blood samples for propofol assays were collected at 1, 2, 3, 5, 10, 20, 40 and 60 min post-induction, and at 0, 1, 3, 5, and 10 min after stopping the infusion. A three compartment effect site model linked to a Sigmoidal Emax PD model, will be used to fit all the data simultaneously in NONMEM. Median performance errors(MDPE), and median absolute performance errors(MDAPE) were calculated to measure bias and accuracy of each model. Comparisons between models will be performed.

02

Conditions studied

  • Propofol Overdose of Undetermined Intent

Browse trials for

Keywords

  • PKPD
  • Propofol
  • TCI
  • Elderly patients
03

In context

Drug Overdose

139 studies on the registry are indexed under Drug Overdose; 24 are open to participants now.

This study's enrollment of 14 is below the median of 175 across 38 observational studies indexed under Drug Overdose.

Browse Drug Overdose studies →

Lead sponsor

Universidad del Desarrollo is the lead sponsor of 23 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients older than 65 years, ASA 1,2 programed for elective sugery

Inclusion criteria

  • Patients older than 65 years, ASA 1,2

Exclusion criteria

Exclusion Criteria:

  • Included less than 70% or more than 130% of ideal body weight
  • Neurologic disorder
  • Use of psychoactive medication, including alcohol intake during the last 48 hours
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
14 participants (actual)
Biospecimen retention
Samples with dna
06

Study locations

2 sites
  • Clinica Alemana de Santiago
    Santiago, 76534, Chile
  • Clinica Alemana Santiago
    Santiago, 76534, Chile
07

References and documents

Individual participant data

Plan to share: Yes — Open TCI proyect

No publications or documents are linked to this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01435785
Lead sponsor
Universidad del Desarrollo
Collaborators
Pontificia Universidad Catolica de Chile
Responsible party
Pablo O. Sepulveda (MD Professor, Universidad del Desarrollo) — Principal investigator
First posted
Sep 19, 2011
Start date
Apr 2011
Primary completion
Sep 2011
Completion
Dec 2011
Last update
Mar 29, 2017

Study contacts

Pablo O Sepulveda, MD
principal investigator · Clinica Alemana Universidad del Desarrollo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion